WT1 Vaccine Nears Approval as Second-Line Mesothelioma Treatment

The WT1 vaccine moves closer to becoming the first FDA-approved, second-line treatment for malignant pleural mesothelioma. Kicking off this summer, the phase III clinical trial is expected to build on the recent, impressive success of a phase II trial that helped the vaccine obtain the U.S. Food and Drug Administration’s orphan drug designation. “We don’t want to overpromise at this point, but this could be quite exciting,” Dr. Andres Gutierrez, chief medical officer for Sellas Life Sciences Group, the biopharmaceutical company developing the vaccine, told Asbestos.com. “We believe we are on the right track.” The earlier, double-blind placebo-controlled trial included 40 patients with mesothelioma who already had completed first-line, multimodal treatment. Those receiving the WT1 vaccine had a median overall survival of 21.4 months, according to recently published data. Those receiving the placebo had a median overall survival of 16.6 months. The median progression-free survival was 11.4 months for those getting the vaccine, compared to 5.7 months for the control arm. “We believe the vaccine can help prolong control of this disease, prolong survival time,” said Dr. Angelos Stergiou, chairman and chief executive officer at Sellas. “That’s our aim, to establish the beneficial effect through this next trial. This vaccine is well-tolerated and capable of inducing a robust immune response. We’re all v...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news

Related Links:

Source: Clinics - Category: General Medicine Source Type: research
CONCLUSIONS: The screening test showed high diagnostic efficiency in determining the risk of language disorders in children aged between 0 and 5 years.
Source: Clinics - Category: General Medicine Source Type: research
CONCLUSION: Survival across the two time periods remained stable for oral SCC but showed a significant increase for oropharyngeal SCC, possibly because of improvements in the patients ’ response to radiotherapy, such as intensity-modulated radiation therapy, and the use of more accurate diagnostic imaging approaches.
Source: Clinics - Category: General Medicine Source Type: research
OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of “ MEC ” (mitoxantrone, etoposide, and cytarabine) and “ FLAG-IDA ” (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) ...
Source: Clinics - Category: General Medicine Source Type: research
ABSTRACT Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first recommendations about the management of HCC. Since then, new data have emerged in the literature, prompting the governing board of SBH to sponsor a single-topic meeting in August 2018 in S ão Paulo. All the invited experts were asked to make a systematic review of the literature reviewing the management of HCC in subjects with cirrhosis. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration o...
Source: Arquivos de Gastroenterologia - Category: Gastroenterology Source Type: research
No abstract available
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Editorial Source Type: research
This study was conducted at the Radiation-Oncology Department of a tertiary center. PATIENTS: Patients with rectal cancer,
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
BACKGROUND: Minimally invasive surgical techniques are routinely promoted as alternatives to open surgery because of improved outcomes. However, the impact of robotic surgery on certain subsets of the population, such as frail patients, is poorly understood. OBJECTIVE: The purpose of our study was to examine the association between frailty and minimally invasive surgical approaches with colon cancer surgery. DESIGN: This is a retrospective study of prospectively collected outcomes data. Thirty-day surgical outcomes were compared by frailty and surgical approach using doubly robust multivariable logistic regression ...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
CONCLUSIONS: Overall survival was good in both subgroups and comparable to literature. The mean costs per patient differ between the watch-and-wait subgroup (€6713) and the total mesorectal excision subgroup (€17,108). No comparison between the groups could be made. Based on the results of this study, the current strategy, where patients with a clinical complete response are treated in a watch-and-wait policy, and patients with an incomplete response are treated with total mesorectal excision, is likely to be (cost)saving. See Video Abstract at http://links.lww.com/DCR/B177. RESULTADOS ONCOLÓGICOS Y COS...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
CONCLUSIONS: Anastomotic leak after oncologic right hemicolectomy is a frequent complication, and it is associated with increased mortality. The key contributing surgical factors for anastomotic leak were anastomotic technique, surgical approach, and duration of surgery. See Video Abstract at http://links.lww.com/DCR/B165. Predictores de Fuga Anastomótica, Complicaciones Postoperatorias y Mortalidad Después de la Colectomía Derecha por Cáncer: Resultados de Una Auditoría Internacional de Corto Plazo ANTECEDENTES: La hemicolectomía derecha se encuentra entre las operaciones m&...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Asbestosis | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Conferences | Environmental Health | Leukemia | Mesothelioma | Myeloma | Neurology | Ovarian Cancer | Ovaries | Rare Diseases | Vaccines